{
    "clinical_study": {
        "@rank": "4870", 
        "arm_group": [
            {
                "arm_group_label": "Delica Lancing Device", 
                "description": "Subjects in this group either use the Delica lancing device or a meter that requires 1.0 microliters of blood"
            }, 
            {
                "arm_group_label": "Freestyle Flash Lancing Device", 
                "description": "Subjects in this group either use the Flash lancing device or a meter that requires 0.3/0.6 microliters of blood"
            }, 
            {
                "arm_group_label": "Easy Touch Lancing Device", 
                "description": "Subjects in this group either use the Easy Touch lancing device or a meter that requires 0.3/0.6 microliters of blood"
            }, 
            {
                "arm_group_label": "Glucoject Lancing Device", 
                "description": "Subjects in this group either use the Glucoject lancing device or a meter that requires 0.3/0.6 microliters of blood"
            }, 
            {
                "arm_group_label": "Microlet Lancing Device", 
                "description": "Subjects in this group either use the Microlet lancing device or a meter that requires 0.3/0.6 microliters of blood"
            }, 
            {
                "arm_group_label": "Multiclix Lancing Device", 
                "description": "Subjects in this group either use the Multiclix lancing device or a meter that requires 0.3/0.6 microliters of blood"
            }, 
            {
                "arm_group_label": "Fastclix Lancing Device", 
                "description": "Subjects in this group either use the Fastclix lancing device or a meter that requires 0.3/0.6 microliters of blood"
            }, 
            {
                "arm_group_label": "Reli-On Lancing Device", 
                "description": "Subjects in this group either use the Reli-On lancing device or a meter that requires 0.3/0.6 microliters of blood"
            }
        ], 
        "brief_summary": {
            "textblock": "Characterize expressed blood volume \u22651\u03bcL across representative, commercially available\n      lancing device systems using finger sticks."
        }, 
        "brief_title": "The Characterization of Blood Volumes of Commercially Available Lancing Devices", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Diabetes", 
        "detailed_description": {
            "textblock": "Primary Objective:\n\n      \u2022 Characterize expressed blood volume \u22651\u03bcL across representative, commercially available\n      lancing device systems using finger sticks.\n\n      Secondary Objectives: the following characterizations will be performed in the data analysis\n      within each device and across each device:\n\n        -  Correlation of Subject pain response to blood volume collected;\n\n        -  Proportion of Subjects that produce sufficient blood to fill a 1\u00b5l test strip;\n\n        -  Proportion of Subjects that generate \u22651\u00b5l blood volume;\n\n        -  Proportion of Subjects who generate multiple- times the blood volume needed to fill a\n           1\u00b5l test strip\n\n        -  Proportion of Subjects who generate multiple- times \u22651\u00b5l of blood volume\n\n        -  Proportion of Subjects that produce on average (\u22651\u00b5l) of blood volume on 1st attempt\n\n        -  Proportion of Subjects that produce on average (\u22651\u00b5l) of blood volume on their first\n           and second lancing attempt"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must be diagnosed with type 1 or type 2 diabetes for one (1) or more  year(s).\n\n          -  Must be currently self-monitoring blood glucose levels for at least 6 months.\n\n          -  Must self-test at least 2 times daily.\n\n          -  Must be between the ages of 18 and 75 to participate.\n\n          -  Subjects must be able to perform all tasks required in this protocol.\n\n          -  Subjects must be willing to complete all study procedures.\n\n          -  Subjects must be able to speak, read and understand English and understand the\n             Informed Consent document.\n\n        Exclusion Criteria:\n\n          -  Subjects with neuropathy or any other nerve damage in the hand or fingers (this will\n             be discovered through the monofilament test)\n\n          -  Subjects who are taking prescription anti-coagulants or more than one full aspirin\n             per day during the past week or have clotting problems that may prolong bleeding\n             (persons taking Plavix or a daily low dose aspirin will not be excluded but this will\n             be recorded).\n\n          -  Subjects taking pain relievers within 24 hours.\n\n          -  Subjects with hemophilia or any other bleeding disorder.\n\n          -  Subjects with infection with a blood borne pathogen (e.g., HIV, hepatitis).\n\n          -  Subjects having a condition such as a cognitive disorder, which in the opinion of the\n             Investigator would put the person at risk or seriously compromise the integrity of\n             the study (PI will sign Case Report Form if Subject is excluded).\n\n          -  Subjects working for Facet, LifeScan Inc., or a competitive company.\n\n          -  Subjects with missing digits.\n\n          -  Subjects who are pregnant or nursing.\n\n          -  Subjects on chemotherapy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "People with diabetes"
            }
        }, 
        "enrollment": {
            "#text": "64", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01914302", 
            "org_study_id": "FT6000682013"
        }, 
        "intervention": [
            {
                "arm_group_label": "Delica Lancing Device", 
                "description": "Characterize Blood Volume and Pain under normal use circumstances", 
                "intervention_name": "Delica Lancing Device", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Freestyle Flash Lancing Device", 
                "description": "Characterize Blood Volume and Pain under normal use circumstances", 
                "intervention_name": "Flash Lancing Device", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Easy Touch Lancing Device", 
                "description": "Characterize Blood Volume and Pain under normal use circumstances", 
                "intervention_name": "Easy Touch Lancing Device", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Glucoject Lancing Device", 
                "description": "Characterize Blood Volume and Pain under normal use circumstances", 
                "intervention_name": "Glucoject Lancing Device", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Microlet Lancing Device", 
                "description": "Characterize Blood Volume and Pain under normal use circumstances", 
                "intervention_name": "Microlet Lancing Device", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Multiclix Lancing Device", 
                "description": "Characterize Blood Volume and Pain under normal use circumstances", 
                "intervention_name": "Multiclix Lancing Device", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Fastclix Lancing Device", 
                "description": "Characterize Blood Volume and Pain under normal use circumstances", 
                "intervention_name": "Fastclix Lancing Device", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Reli-On Lancing Device", 
                "description": "Characterize Blood Volume and Pain under normal use circumstances", 
                "intervention_name": "Reli-On Lancing Device", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 1, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kennesaw", 
                    "country": "United States", 
                    "state": "Georgia", 
                    "zip": "30144"
                }, 
                "name": "Facet Technologies"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "8", 
        "official_title": "Lancing Device Blood Volume Study", 
        "overall_official": {
            "last_name": "Barry Ginsberg, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Study subject lances assigned finger and acquires blood drop; at that time the study facilitator gathers blood in pipette and measures on scale", 
            "measure": "Blood Volumes measured in microliters", 
            "safety_issue": "No", 
            "time_frame": "between 1 and 10 days after first visit"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01914302"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Subjects were asked to rate pain on Gracely scale after each lancing even on the finger", 
            "measure": "Pain rating measure on a 0-20 Gracely Scale", 
            "safety_issue": "No", 
            "time_frame": "between 1 and 10 days after first visit"
        }, 
        "source": "Facet Technologies", 
        "sponsors": {
            "collaborator": {
                "agency": "LifeScan", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Facet Technologies", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "August 2013"
    }
}